Nuvilex Inc (NVLX) 0.2200 $NVLX
Cannabis Support on the Rise as Nuvilex and mCig Move Higher
ACCESSWIRE - Mon Sep 08, 11:01AM CDT
WHITEFISH, MT / September 8, 2014 / Cannabis stocks moved largely lower over the past week amid ongoing profit taking following the industry's run-up over the past year. Top gainers for the week included Nuvilex Inc. (OTC: NVLX) earlier in the week following its application for orphan status for its pancreatic cancer treatment and mCig Inc. (OTC: MCIG) late in the week following the trademarking of two brands.
Nuvilex's Partner, Austrianova, Receives Prestigious Emerging Enterprises 2014 Best Innovation Award in Singapore
GlobeNewswire - Fri Sep 05, 12:22PM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that its partner, Austrianova, has received the Emerging Enterprises Best Innovation Award for 2014 in Singapore for its innovative Cell-in-a-Box and Bac-in-a-Box cell encapsulation technologies. The award was received at a gala ceremony in Singapore that was hosted by the OCBC bank. The Innovation award was sponsored by SingTel.
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology
ACCESSWIRE - Fri Sep 05, 8:06AM CDT
New York, NY / ACCESSWIRE / September 5, 2014 / Nuvilex, Inc. (OTCQB: NVLX) has used the last two weeks to further solidify its position as a biotechnology firm, and to further its treatment for advanced pancreatic cancer, as well as, other abdominal cancers. This summer has been a starting line, of sorts, for Nuvilex to begin making the case that Cell-in-a-Box(r) should help it become a competitor in the cancer market.
Nuvilex Submits Application for Orphan Drug Designation to the European Medicines Agency for Its Cell-in-a-Box(R) Treatment for Pancreatic Cancer
GlobeNewswire - Tue Sep 02, 8:58AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has submitted an application to the European Medicines Agency (EMA) for an Orphan Drug Designation for its Cell-in-a-Box treatment for pancreatic cancer. Nuvilex's pancreatic cancer treatment consists of the combination of Cell-in-a-Box with low doses of the anticancer drug ifosfamide. The Cell-in-a-Box portion of the treatment consists of live cells capable of converting ifosfamide into its cancer-killing form that have been enclosed in protective pin-head sized spherical capsules that are composed of bio-inert cellulose.
Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex's Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid
GlobeNewswire - Wed Aug 20, 8:29AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development's (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex's unique cancer treatment can slow the accumulation of fluid, known as "malignant ascites," in the abdomen that is characteristic of the growth of many abdominal tumors.
Nuvilex Announces Publication of Combined Results of the Initial Phase 1/2 Clinical Trial and a Second Phase 2 Clinical Trial of the Cell-in-a-Box(R) Plus Ifosfamide Combination in Patients With Advanced, Inoperable Pancreatic Cancer
GlobeNewswire - Thu Aug 14, 8:06AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its partner, Austrianova, has reported the results from the second Phase 2 clinical trial combining the Cell-in-a-Box cellulose-based live cell encapsulation technology plus low doses of the anticancer prodrug ifosfamide in patients with advanced, inoperable cancer has been published in the scientific journal Pharmaceutics. The title of the publication is "Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical Trials in Pancreatic Cancer." The entire report can be viewed by clicking http://www.mdpi.com/1999-4923/6/3/447 and then clicking on "Full-Text PDF" on the left side of the page.
Small Business Operations to Large Scale Companies Take Steps to Increase Security Surveillance - Company Selected for Comprehensive Cannabis Security System Installation
PR Newswire - Thu Aug 14, 8:05AM CDT
Security and Surveillance needs become top priority in Cannabis / Legal Marijuana industry as sector continues expansion and growth for the following emerging companies: DirectView Holdings, Inc. (OTC: DIRV), Nuvilex, Inc. (OTC: NVLX), GW Pharmaceuticals plc (NASDAQ: GWPH), Singlepoint, Inc. (OTC: SING) and Cannabis Science, Inc. (CBIS).
Nuvilex Provides Update on Status of Preclinical Studies at Translational Drug Development
GlobeNewswire - Wed Aug 13, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it is providing shareholders with an update on the status of Nuvilex's preclinical studies to be conducted by Translational Drug Development (TD2) in Scottsdale, Arizona.
Nuvilex Announces That Dr. Richard M. Hyslop Will Present at the ACS Annual Meeting on "Sustainable, Green Chemistry and Medicine: Targeted Cannabinoid-Based Chemotherapy Utilizing Cell-in-a-Box(R) Live Cell Encapsulation Technology."
GlobeNewswire - Mon Aug 04, 8:46AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Dr. Richard M. Hyslop, Professor of Chemistry and Biochemistry at the University of Northern Colorado (UNC) and member of the Scientific Advisory Board of Nuvilex's subsidiary, Medical Marijuana Sciences, and Dr. Corina Brown of UNC will be presenting at the 248 American Chemical Society National Meeting & Exposition being held in San Francisco, California, August 10-14, 2014. The theme for this year's meeting is "Chemistry and Global Stewardship".
OTC Trading Stock News: Digipath, Inc. Immune Pharmaceuticals, Inc. Vuzix Corp, Nuvilex, Inc. Origin Oil, Inc.
PR Newswire Europe - Tue Jul 29, 7:07AM CDT
LONDON, July 29, 2014 /PRNewswire/ --
Nuvilex Nears Crucial Quality of Life Study in Malignant Ascites Associated with Pancreatic and Other Abdominal Cancers
ACCESSWIRE - Wed Jul 23, 8:01AM CDT
New York, NY / ACCESSWIRE / July 23, 2014 / Nuvilex, Inc. (OTCQB: NVLX) will begin preclinical studies in early August with its Contract Research Organization (CRO) Translational Drug Development (TD2) to study the first of 4 symptoms associated with pancreatic cancer and other abdominal cancers. In what is essentially the biggest step in Nuvilex's history to date, the company will enter the clinic under its own brand for the first time ever, and it will do so with the highly respected oncology CRO, TD2 and its Chief Development Officer, Dr. Daniel Von Hoff. In the studies, Nuvilex and TD2 will determine what effect the company's pancreatic cancer treatment will have on these symptoms.
Cannabis Stocks Edge Higher Last Week Led by Nuvilex & Entertopia
ACCESSWIRE - Tue Jul 22, 8:32AM CDT
WHITEFISH, MT / July 22, 2014 / The Marijuana Index(TM) moved slightly higher last week, despite a 7% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares. Medbox Inc. (OTC: MDBX), the second largest component of the index, also fell over 5% last week.
Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs with Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyclophosphamide
GlobeNewswire - Thu Jul 17, 9:25AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced, in cooperation with its partner Austrianova, the results of a veterinary Phase I/II clinical trial in dogs with mammary tumors who were treated with Cell-in-a-Box cellulose-based live cell encapsulation plus the widely used anticancer drug cyclophosphamide (Cytoxan). These results were published in the Public Library of Science journal (PLOS ONE) on July 16, 2014.
Cannabis Stocks Move Higher as Washington State Pot Sales Begin
ACCESSWIRE - Mon Jul 14, 8:30AM CDT
WHITEFISH, MT / July 14, 2014 / The Marijuana Index(TM) moved higher last week in the aggregate, despite a 13% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares and a roughly 1.5% drop in Medbox Inc. (OTC: MDBX) shares, which comprise about half of the weighted index.
Nuvilex Provides Shareholder Update on Milestone Accomplishments
GlobeNewswire - Mon Jul 14, 8:01AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today issued the following shareholder update letter from Kenneth L. Waggoner, CEO and President.
Nuvilex Analyst Report: Potentially Revolutionary Technology Positions Biopharmaceutical Firm as a Cancer Market Competitor - Fundamentals Need to Catch up With Expectations by BrokerBank Securities, Inc.
PR Newswire - Mon Jul 14, 6:45AM CDT
Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biopharmaceutical competitor is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box®. This unique technology is intended for use as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.
Nuvilex Scheduled to Begin Preclinical Studies in Early August
GlobeNewswire - Wed Jul 09, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that all preparations for the commencement of its preclinical studies to determine the effectiveness of Nuvilex's pancreatic cancer treatment in slowing down the accumulation of ascites fluid have been completed. As previously announced, Translational Drug Development, LLC (TD2) will conduct the study. Ascites fluid accumulates in the abdomen and is usually associated with the development of advanced pancreatic and other abdominal cancers.
Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market
Marketwire - Mon Jul 07, 8:01AM CDT
Nuvilex, Inc. (OTCQB: NVLX) announced last week that its executives recently met with the company's "global development partners" at the 2014 BIO International Convention in San Diego. One of the meetings that CEO Ken Waggoner and COO Dr. Gerald Crabtree held was with a representative of the Juvenile Diabetes Research Foundation (JDRF) to discuss Nuvilex's plans for treating diabetes. This, of course, begs the question -- is Nuvilex in line for a partnership to bring its diabetes treatment to market?
Nuvilex Executives Attend 2014 BIO International Convention
GlobeNewswire - Tue Jul 01, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Chief Executive Officer and President Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree attended the 2014 BIO International Convention held June 23-26, 2014, in San Diego, California. The event allowed the CEO and COO to spend valuable time with Cell-in-a-Box co-developers, Drs. Walter Gunzburg and Brian Salmons, Clinical Network Services of Australia who will conduct Nuvilex's Phase 2b clinical trial in pancreatic cancer and with a representative of the Juvenile Diabetes Research Foundation about Nuvilex's plans for treating diabetes.
Cannabis Support on the Rise as Nuvilex and mCig Move Higher
ACCESSWIRE - Mon Sep 08, 11:01AM CDT
WHITEFISH, MT / September 8, 2014 / Cannabis stocks moved largely lower over the past week amid ongoing profit taking following the industry's run-up over the past year. Top gainers for the week included Nuvilex Inc. (OTC: NVLX) earlier in the week following its application for orphan status for its pancreatic cancer treatment and mCig Inc. (OTC: MCIG) late in the week following the trademarking of two brands.
Nuvilex's Partner, Austrianova, Receives Prestigious Emerging Enterprises 2014 Best Innovation Award in Singapore
GlobeNewswire - Fri Sep 05, 12:22PM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that its partner, Austrianova, has received the Emerging Enterprises Best Innovation Award for 2014 in Singapore for its innovative Cell-in-a-Box and Bac-in-a-Box cell encapsulation technologies. The award was received at a gala ceremony in Singapore that was hosted by the OCBC bank. The Innovation award was sponsored by SingTel.
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology
ACCESSWIRE - Fri Sep 05, 8:06AM CDT
New York, NY / ACCESSWIRE / September 5, 2014 / Nuvilex, Inc. (OTCQB: NVLX) has used the last two weeks to further solidify its position as a biotechnology firm, and to further its treatment for advanced pancreatic cancer, as well as, other abdominal cancers. This summer has been a starting line, of sorts, for Nuvilex to begin making the case that Cell-in-a-Box(r) should help it become a competitor in the cancer market.
Nuvilex Submits Application for Orphan Drug Designation to the European Medicines Agency for Its Cell-in-a-Box(R) Treatment for Pancreatic Cancer
GlobeNewswire - Tue Sep 02, 8:58AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has submitted an application to the European Medicines Agency (EMA) for an Orphan Drug Designation for its Cell-in-a-Box treatment for pancreatic cancer. Nuvilex's pancreatic cancer treatment consists of the combination of Cell-in-a-Box with low doses of the anticancer drug ifosfamide. The Cell-in-a-Box portion of the treatment consists of live cells capable of converting ifosfamide into its cancer-killing form that have been enclosed in protective pin-head sized spherical capsules that are composed of bio-inert cellulose.
Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex's Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid
GlobeNewswire - Wed Aug 20, 8:29AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development's (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex's unique cancer treatment can slow the accumulation of fluid, known as "malignant ascites," in the abdomen that is characteristic of the growth of many abdominal tumors.
Nuvilex Announces Publication of Combined Results of the Initial Phase 1/2 Clinical Trial and a Second Phase 2 Clinical Trial of the Cell-in-a-Box(R) Plus Ifosfamide Combination in Patients With Advanced, Inoperable Pancreatic Cancer
GlobeNewswire - Thu Aug 14, 8:06AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its partner, Austrianova, has reported the results from the second Phase 2 clinical trial combining the Cell-in-a-Box cellulose-based live cell encapsulation technology plus low doses of the anticancer prodrug ifosfamide in patients with advanced, inoperable cancer has been published in the scientific journal Pharmaceutics. The title of the publication is "Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical Trials in Pancreatic Cancer." The entire report can be viewed by clicking http://www.mdpi.com/1999-4923/6/3/447 and then clicking on "Full-Text PDF" on the left side of the page.
Small Business Operations to Large Scale Companies Take Steps to Increase Security Surveillance - Company Selected for Comprehensive Cannabis Security System Installation
PR Newswire - Thu Aug 14, 8:05AM CDT
Security and Surveillance needs become top priority in Cannabis / Legal Marijuana industry as sector continues expansion and growth for the following emerging companies: DirectView Holdings, Inc. (OTC: DIRV), Nuvilex, Inc. (OTC: NVLX), GW Pharmaceuticals plc (NASDAQ: GWPH), Singlepoint, Inc. (OTC: SING) and Cannabis Science, Inc. (CBIS).
Nuvilex Provides Update on Status of Preclinical Studies at Translational Drug Development
GlobeNewswire - Wed Aug 13, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it is providing shareholders with an update on the status of Nuvilex's preclinical studies to be conducted by Translational Drug Development (TD2) in Scottsdale, Arizona.
Nuvilex Announces That Dr. Richard M. Hyslop Will Present at the ACS Annual Meeting on "Sustainable, Green Chemistry and Medicine: Targeted Cannabinoid-Based Chemotherapy Utilizing Cell-in-a-Box(R) Live Cell Encapsulation Technology."
GlobeNewswire - Mon Aug 04, 8:46AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Dr. Richard M. Hyslop, Professor of Chemistry and Biochemistry at the University of Northern Colorado (UNC) and member of the Scientific Advisory Board of Nuvilex's subsidiary, Medical Marijuana Sciences, and Dr. Corina Brown of UNC will be presenting at the 248 American Chemical Society National Meeting & Exposition being held in San Francisco, California, August 10-14, 2014. The theme for this year's meeting is "Chemistry and Global Stewardship".
OTC Trading Stock News: Digipath, Inc. Immune Pharmaceuticals, Inc. Vuzix Corp, Nuvilex, Inc. Origin Oil, Inc.
PR Newswire Europe - Tue Jul 29, 7:07AM CDT
LONDON, July 29, 2014 /PRNewswire/ --
Nuvilex Nears Crucial Quality of Life Study in Malignant Ascites Associated with Pancreatic and Other Abdominal Cancers
ACCESSWIRE - Wed Jul 23, 8:01AM CDT
New York, NY / ACCESSWIRE / July 23, 2014 / Nuvilex, Inc. (OTCQB: NVLX) will begin preclinical studies in early August with its Contract Research Organization (CRO) Translational Drug Development (TD2) to study the first of 4 symptoms associated with pancreatic cancer and other abdominal cancers. In what is essentially the biggest step in Nuvilex's history to date, the company will enter the clinic under its own brand for the first time ever, and it will do so with the highly respected oncology CRO, TD2 and its Chief Development Officer, Dr. Daniel Von Hoff. In the studies, Nuvilex and TD2 will determine what effect the company's pancreatic cancer treatment will have on these symptoms.
Cannabis Stocks Edge Higher Last Week Led by Nuvilex & Entertopia
ACCESSWIRE - Tue Jul 22, 8:32AM CDT
WHITEFISH, MT / July 22, 2014 / The Marijuana Index(TM) moved slightly higher last week, despite a 7% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares. Medbox Inc. (OTC: MDBX), the second largest component of the index, also fell over 5% last week.
Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs with Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyclophosphamide
GlobeNewswire - Thu Jul 17, 9:25AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced, in cooperation with its partner Austrianova, the results of a veterinary Phase I/II clinical trial in dogs with mammary tumors who were treated with Cell-in-a-Box cellulose-based live cell encapsulation plus the widely used anticancer drug cyclophosphamide (Cytoxan). These results were published in the Public Library of Science journal (PLOS ONE) on July 16, 2014.
Cannabis Stocks Move Higher as Washington State Pot Sales Begin
ACCESSWIRE - Mon Jul 14, 8:30AM CDT
WHITEFISH, MT / July 14, 2014 / The Marijuana Index(TM) moved higher last week in the aggregate, despite a 13% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares and a roughly 1.5% drop in Medbox Inc. (OTC: MDBX) shares, which comprise about half of the weighted index.
Nuvilex Provides Shareholder Update on Milestone Accomplishments
GlobeNewswire - Mon Jul 14, 8:01AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today issued the following shareholder update letter from Kenneth L. Waggoner, CEO and President.
Nuvilex Analyst Report: Potentially Revolutionary Technology Positions Biopharmaceutical Firm as a Cancer Market Competitor - Fundamentals Need to Catch up With Expectations by BrokerBank Securities, Inc.
PR Newswire - Mon Jul 14, 6:45AM CDT
Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biopharmaceutical competitor is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box®. This unique technology is intended for use as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.
Nuvilex Scheduled to Begin Preclinical Studies in Early August
GlobeNewswire - Wed Jul 09, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that all preparations for the commencement of its preclinical studies to determine the effectiveness of Nuvilex's pancreatic cancer treatment in slowing down the accumulation of ascites fluid have been completed. As previously announced, Translational Drug Development, LLC (TD2) will conduct the study. Ascites fluid accumulates in the abdomen and is usually associated with the development of advanced pancreatic and other abdominal cancers.
Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market
Marketwire - Mon Jul 07, 8:01AM CDT
Nuvilex, Inc. (OTCQB: NVLX) announced last week that its executives recently met with the company's "global development partners" at the 2014 BIO International Convention in San Diego. One of the meetings that CEO Ken Waggoner and COO Dr. Gerald Crabtree held was with a representative of the Juvenile Diabetes Research Foundation (JDRF) to discuss Nuvilex's plans for treating diabetes. This, of course, begs the question -- is Nuvilex in line for a partnership to bring its diabetes treatment to market?
Nuvilex Executives Attend 2014 BIO International Convention
GlobeNewswire - Tue Jul 01, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Chief Executive Officer and President Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree attended the 2014 BIO International Convention held June 23-26, 2014, in San Diego, California. The event allowed the CEO and COO to spend valuable time with Cell-in-a-Box co-developers, Drs. Walter Gunzburg and Brian Salmons, Clinical Network Services of Australia who will conduct Nuvilex's Phase 2b clinical trial in pancreatic cancer and with a representative of the Juvenile Diabetes Research Foundation about Nuvilex's plans for treating diabetes.
